Respiratory Intensive Care Unit, City Hospital of Padova, Padova, Italy.
Respiratory Intensive Care Unit, City Hospital of Padova, Padova, Italy.
J Crit Care. 2011 Oct;26(5):517-524. doi: 10.1016/j.jcrc.2010.12.008. Epub 2011 Jan 26.
A substantial proportion of patients with neuromuscular disease (NMD) who undergo positive pressure ventilation via endotracheal intubation for acute respiratory failure fail to pass spontaneous breathing trials and should be considered at high risk for extubation failure. In our study, we prospectively investigated the efficacy of early application of noninvasive ventilation (NIV) combined with assisted coughing as an intervention aimed at preventing extubation failure in patients with NMD.
This study is a prospective analysis of the short-term outcomes of 10 patients with NMD who were treated by NIV and assisted coughing immediately after extubation and comparison with the outcomes of a population of 10 historical control patients who received standard medical therapy (SMT) alone. The participants were composed of 10 patients with NMD who were submitted to NIV and assisted coughing after extubation (group A) and 10 historical control patients who were administered SMT (group B), who were admitted to a 4-bed respiratory intensive care unit (RICU) in a university hospital. Need for reintubation despite treatment was evaluated. Mortality during RICU stay, need for tracheostomy, and length of stay in the RICU were also compared.
Significantly fewer patients who received the treatment protocol required reintubation and tracheostomy compared with those who received SMT (reintubation, 3 vs 10; tracheostomy, 3 vs 9; P = .002 and .01, respectively). Mortality did not differ significantly between the 2 groups. Patients in group A remained for a shorter time in the RICU compared with group B (7.8 ± 3.9 vs 23.8 ± 15.8 days; P = .006).
Preventive application of NIV combined with assisted coughing after extubation provides a clinically important advantage to patients with NMD by averting the need for reintubation or tracheostomy and shortening their stay in the RICU; its use should be included in the routine approach to patients with NMD at high risk for postextubation respiratory failure.
相当一部分因急性呼吸衰竭而通过气管内插管接受正压通气的神经肌肉疾病(NMD)患者未能通过自主呼吸试验,应被视为拔管失败的高风险患者。在我们的研究中,我们前瞻性地研究了早期应用无创通气(NIV)联合辅助咳嗽预防 NMD 患者拔管失败的疗效。
本研究是对 10 例 NMD 患者拔管后立即接受 NIV 和辅助咳嗽治疗的短期结果的前瞻性分析,并与仅接受标准药物治疗(SMT)的 10 例历史对照患者的结果进行比较。研究对象由 10 例 NMD 患者组成,他们在拔管后接受 NIV 和辅助咳嗽(A 组),以及 10 例接受 SMT(B 组)的历史对照患者组成,他们入住一所大学医院的 4 床呼吸重症监护病房(RICU)。评估了尽管进行了治疗仍需要重新插管的情况。还比较了 RICU 住院期间的死亡率、需要气管切开术和 RICU 住院时间。
与接受 SMT 的患者相比,接受治疗方案的患者需要重新插管和气管切开术的患者明显减少(重新插管,3 例与 10 例;气管切开术,3 例与 9 例;P =.002 和.01)。两组死亡率无显著差异。与 B 组相比,A 组患者在 RICU 中的时间更短(7.8 ± 3.9 与 23.8 ± 15.8 天;P =.006)。
拔管后预防性应用 NIV 联合辅助咳嗽为 NMD 患者提供了重要的临床优势,避免了重新插管或气管切开术的需要,并缩短了他们在 RICU 的住院时间;应将其纳入高危拔管后呼吸衰竭患者的常规治疗方法。